Targeted acetylcholinesterase-responsive drug carriers with long duration of drug action and reduced hepatotoxicity

References

• Allen RK. A review of angiotensin converting enzyme in health and disease. Sarcoidosis. 1991;8(2):95–100.1670005
   PubMedGoogle Scholar
• Darveau CA, Suarez RK, Andrews RD, Hochachka PW. Allometric cascade as a unifying principle of body mass effects on metabolism. Nature. 2002;417(6885):166–170. doi:10.1038/417166a12000958
   PubMedGoogle Scholar
• Holmström KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signaling. Nat Rev Mol Cell Biol. 2014;15(6):411–421. doi:10.1038/nrm380124854789
   PubMed Web of Science ®Google Scholar
• Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet. 2000;26(2):151–157. doi:10.1038/7986611017069
   PubMedGoogle Scholar
• Riley DP. Functional mimics of superoxide dismutase enzymes as therapeutic agents. Chem Rev. 1999;99(9):2573–2588.11749493
   PubMed Web of Science ®Google Scholar
• López-Otín C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008;283(45):30433–30437. doi:10.1074/jbc.R80003520018650443
   PubMed Web of Science ®Google Scholar
• Zimmerman G, Soreq H. Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res. 2006;326(2):655–669. doi:10.1007/s00441-006-0239-816802134
   PubMedGoogle Scholar
• Soreq H, Seidman S. Acetylcholinesterase – new roles for an old actor. Nat Rev Neurosci. 2001;2(4):294–302. doi:10.1038/3506758911283752
   PubMed Web of Science ®Google Scholar
• Dawson RM. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett. 1990;118(1):85–87. doi:10.1016/0304-3940(90)90254-72259472
   PubMedGoogle Scholar
• Wlodek ST, Clark TW, Scott LR, McCammon JA. Molecular dynamics of acetylcholinesterase dimer complexed with tacrine. J Am Chem Soc. 1997;119(40):9513–9522. doi:10.1021/ja971226d
   Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998;8(1):67–75.9452942
   PubMed Web of Science ®Google Scholar
• Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res. 2005;1033(2):186–193. doi:10.1016/j.brainres.2004.11.04215694923
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20(4):634–647.9737824
   PubMed Web of Science ®Google Scholar
• Bar-On P, Millard CB, Harel M, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry. 2002;41(11):3555–3564. doi:10.1021/bi020016x11888271
   PubMed Web of Science ®Google Scholar
• Lewis WG, Green LG, Grynszpan F, et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl. 2002;41(6):1053–1057.12491310
   PubMed Web of Science ®Google Scholar
• Krasiński A, Radić Z, Manetsch R, et al. In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors. J Am Chem Soc. 2005;127(18):6686–6692. doi:10.1021/ja043031t15869290
   PubMedGoogle Scholar
• Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J Med Chem. 2007;50(26):6446–6449. doi:10.1021/jm701225u18047264
   PubMed Web of Science ®Google Scholar
• Catto M, Pisani L, Leonetti F, et al. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg Med Chem. 2013;21(1):146–152. doi:10.1016/j.bmc.2012.10.04523199476
   PubMedGoogle Scholar
• Chen C, Geng J, Pu F, Yang XJ, Ren JS, Qu XG. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery. Angew Chem Int Ed Engl. 2011;50(4):882–886. doi:10.1002/anie.20100547121246683
   PubMed Web of Science ®Google Scholar
• Yang XJ, Liu X, Liu Z, Pu F, Ren JS, Qu XG. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater. 2012;24(21):2890–2895. doi:10.1002/adma.20110479722539076
   PubMed Web of Science ®Google Scholar
• Chen ZW, Li ZH, Lin YH, Yin ML, Ren JS, Qu XG. Biomineralization inspired surface engineering of nanocarriers for pH-responsive, targeted drug delivery. Biomaterials. 2013;34(4):1364–1371. doi:10.1016/j.biomaterials.2012.10.06023140999
   PubMedGoogle Scholar
• Shi P, Qu KG, Wang JS, Li M, Ren JS, Qu XG. pH-responsive NIR enhanced drug release from gold nanocages possesses high potency against cancer cells. Chem Commun. 2012;48(61):7640–7642. doi:10.1039/c2cc33543c
   PubMed Web of Science ®Google Scholar
• Chen ZW, Zhou L, Bing W, et al. Light controlled reversible inversion of nanophosphor-stabilized pickering emulsions for biphasic enantioselective biocatalysis. J Am Chem Soc. 2014;136(20):7498–7504. doi:10.1021/ja503123m24784766
   PubMedGoogle Scholar
• Li M, Liu Z, Ren JS, Qu XG. Inhibition of metal-induced amyloid aggregation using light-responsive magnetic nanoparticle prochelator conjugates. Chem Sci. 2012;3:868–873. doi:10.1039/C1SC00631B
   Web of Science ®Google Scholar
• Luo Z, Cai KY, Hu Y, et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew Chem Int Ed Engl. 2011;50(3):640–643. doi:10.1002/anie.20100506121226142
   PubMed Web of Science ®Google Scholar
• Cho H, Bae J, Garripelli VK, Anderson JM, Jun HW, Jo S. Redox-sensitive polymeric nanoparticles for drug delivery. Chem Commun. 2012;48(48):6043–6045. doi:10.1039/c2cc31463k
   PubMed Web of Science ®Google Scholar
• Lai CY, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc. 2003;125(15):4451–4459. doi:10.1021/ja028650l12683815
   PubMed Web of Science ®Google Scholar
• Singh N, Karambelkar A, Gu L, et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc. 2011;133(49):19582–19585. doi:10.1021/ja206998x21981330
   PubMed Web of Science ®Google Scholar
• Tang FQ, Li LL, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534. doi:10.1002/adma.20110476322378538
   PubMed Web of Science ®Google Scholar
• Trewyn BG, Slowing II, Giri S, Chen HT, Lin VS. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res. 2007;40(9):846–853. doi:10.1021/ar600032u17645305
   PubMed Web of Science ®Google Scholar
• Guo DS, Wang K, Wang YX, Liu Y. Cholinesterase-responsive supramolecular vesicle. J Am Chem Soc. 2012;134(24):10244–10250. doi:10.1021/ja303280r22686862
   PubMed Web of Science ®Google Scholar
• Lv J, He BN, Wang N, Li M, Lin YL. A gold nanoparticle based colorimetric and fluorescent dual-channel probe for acetylcholinesterase detection and inhibitor screening. RSC Adv. 2018;8(57):32893–32898. doi:10.1039/C8RA06165C
   PubMed Web of Science ®Google Scholar
• Guo DS, Liu Y. Supramolecular chemistry of p-sulfonatocalixarenes and its biological applications. Acc Chem Res. 2014;47(7):1925–1934. doi:10.1021/ar500009g24666259
   PubMed Web of Science ®Google Scholar
• Chen M, He XX, Wang KM, et al. A pH-responsive polymer/mesoporous silica nano-container linked through an acid cleavable linker for intracellular controlled release and tumor therapy in vivo. J Mater Chem B. 2014;2(4):428–436. doi:10.1039/C3TB21268H
   PubMed Web of Science ®Google Scholar
• Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm. 2002;109(7–8):1067–1068. doi:10.1007/s00702020009012111444
   PubMedGoogle Scholar
• Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet. 1991;338(11):50–51. doi:10.1016/0140-6736(91)90035-n
   PubMedGoogle Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–998.8139084
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375–399. doi:10.1007/s12272-013-0036-323435942
   PubMed Web of Science ®Google Scholar
• Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc. 2010;132(13):4834–4842. doi:10.1021/ja910846q20230032
   PubMed Web of Science ®Google Scholar
• Yildirim A, Ozgur E, Bayindir M. Impact of mesoporous silica nanoparticle surface functionality on hemolytic activity, thrombogenicity and non-specific protein adsorption. J Mater Chem B. 2013;1(14):1909–1920. doi:10.1039/c3tb20139b
   PubMed Web of Science ®Google Scholar
• Park JH, Gu L, Von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater. 2009;8(4):331–336. doi:10.1038/nmat239819234444
   PubMed Web of Science ®Google Scholar
• Croissant JG, Fatieiev Y, Khashab NM. Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv Mater. 2017;29(9):1604634. doi:10.1002/adma.201700681
   Web of Science ®Google Scholar
• Chen G, Teng Z, Su X, Liu Y, Lu G. Unique biological degradation behavior of Stöber mesoporous silica nanoparticles from their interiors to their exteriors. J Biomed Nanotechnol. 2015;11(4):722–729.26310078
   PubMed Web of Science ®Google Scholar
• Huang X, Li L, Liu T, et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano. 2011;5(7):5390–5399. doi:10.1021/nn200365a21634407
   PubMed Web of Science ®Google Scholar
• He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small. 2011;7(2):271–280. doi:10.1002/smll.20100145921213393
   PubMed Web of Science ®Google Scholar